---
title: "UBS Sticks to Its Hold Rating for Novartis AG (NOVN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285695228.md"
description: "UBS analyst Matthew Weston has maintained a Hold rating on Novartis AG (NOVN) with a price target of CHF116.00. Weston, who focuses on the Healthcare sector, has an average return of 9.9% and a 71.43% success rate on his stock recommendations. Additionally, Bernstein's Justin Smith also rated Novartis as Hold, while J.P. Morgan issued a Buy rating on May 5."
datetime: "2026-05-08T09:06:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285695228.md)
  - [en](https://longbridge.com/en/news/285695228.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285695228.md)
---

# UBS Sticks to Its Hold Rating for Novartis AG (NOVN)

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novartis AG, with a price target of CHF116.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Weston covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Roche Holding AG. According to TipRanks, Weston has an average return of 9.9% and a 71.43% success rate on recommended stocks.

In addition to UBS, Novartis AG also received a Hold from Bernstein’s Justin Smith in a report issued on April 29. However, on May 5, J.P. Morgan maintained a Buy rating on Novartis AG (Six Swiss: NOVN).

### Related Stocks

- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)
- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [AB.US](https://longbridge.com/en/quote/AB.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)